Surveillance in Ulcerative Colitis: Narrow Band Image Versus Chromoendoscopy for High-risk Groups

Summary

The risk of colorectal cancer (CRC) is increased in patients having ulcerative colitis (UC). Patients with long-standing extensive colitis, concomitant primary sclerosing cholangitis, or previous history of dysplasia carry an exceptionally high risk of CRC and require regular and short-interval surveillance colonoscopy. Recent guidelines recommend surveillance colonoscopy based on target biopsy rather than random biopsy applying chromoendoscopy (CE) or narrow band image (NBI) technique in UC at risk for CRC. However, the diagnostic yield of NBI-based surveillance and CE-based surveillance is not extensively investigated in the high-risk UC population. The investigators aimed to compare the dysplasia detection rate of NBI with that of CE in UC patients with a high risk of CRC by performing a multicenter, randomized controlled trial.

Conditions

• Ulcerative Colitis
• Dysplasia

Interventions

DIAGNOSTIC_TEST

chromoendoscopy with target biopsy; NBI with target biopsy

Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia. NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.

Sponsors & Collaborators

• Yonsei University

  collaborator OTHER

• Samsung Medical Center

  collaborator OTHER

• Sungkyunkwan University

  collaborator OTHER

• Ewha Womans University

  collaborator OTHER

• The Catholic University of Korea

  collaborator OTHER

• Soonchunhyang University Hospital

  collaborator OTHER

• Asan Medical Center

  lead OTHER

Principal Investigators

• Dong-Hoon Yang, MD, PhD · Asan Medical Center

Study Design

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

19 Years

Max Age

79 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-12-31

Primary Completion

2022-08-31

Completion

2023-01-31